News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
CR845, a novel, peripherally restricted kappa opioid agonist, is currently in Phase 2 development for treatment of post-operative pain
View HTML
Toggle Summary Cara's No-Brainer Opioid Solution
Cara's No-Brainer Opioid Solution San Carlos, CA, Feb 22, 2010 /The Bernstein Report on BioBusiness/ — Cara Therapeutics, Inc. believes its CR845 kappa opioid agonist will fare better than others because the peptide is too large to cross the blood-brain barrier, meaning it should avoid the side
View HTML
Toggle Summary Cara Therapeutics Reports Positive Phase II Data for Novel Peripheral Analgesic In Acute Post-Operative Pain
Cara Therapeutics Reports Positive Phase II Data for Novel Peripheral Analgesic In Acute Post-Operative Pain Shelton, CT, Feb 8, 2010 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa
View HTML
Toggle Summary Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic In Acute Post-Operative Pain
Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic In Acute Post-Operative Pain Shelton, CT, Jan 12, 2009 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced that it is initiating a Phase II clinical trial of its long-acting peripheral kappa opioid agonist,
View HTML
Toggle Summary Pharmacological Profile of a Novel Series of CB2-Selective Agonists with Efficacy in Visceral, Inflammatory, and Neuropathic Pain" View HTML
Toggle Summary "Preclinical Profile of CR845" View HTML
Toggle Summary Development of the Novel, Peripherally-Selective Kappa Opiod Agonist CR665 for the Treatment of Acute Pain View HTML
Toggle Summary Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845 Cara Therapeutics, Inc. today announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of
View HTML
Toggle Summary Cara Therapeutics Secures $12.3 Million In Series C Extension Financing
Cara Therapeutics Secures $12.3 Million In Series C Extension Financing Cara Therapeutics, Inc. announced today that it had closed on $12.3 million of additional funding to its original $24 million Series C financing which was completed in 2007. The round was led by new investor, Devon Park
View HTML
Toggle Summary Cara Therapeutics Announces Issuance of U.S. Patent Covering Second Generation Kappa Opioid Receptor Agonists
Cara Therapeutics Announces Issuance of U.S. Patent Covering Second Generation Kappa Opioid Receptor Agonists Cara Therapeutics, Inc. announced today that The United States Patent and Trademark Office has issued U.S. Patent No. 7,402,564 entitled “Synthetic Peptide Amides” under its Accelerated
View HTML